Kornimate/medical-research-clean huggingface dataset:
a prospective study to observe the mechanism of action of the meditate itind in subjects with symptomatic bph with mri

Conditions: BPH

Summary: a total of up to 15 eligible subjects will be enrolled into this open-labeled one-arm study designed to observe the mechanism of action of itind when using mri

study objective: to validate the itind efficacy by using mri in subjects with symptomatic bph. specifically the pressure points created by the itind's struts and its implications on blood flow to the prostate will be assessed. efficacy endpoints: the endpoints of this study are: * decrease in transition zone volume * monitor size and location of ablative lesions * monitor change in time of lesions * monitor the correspondence change in prostate tissue all the above will be assessed by using mri.

Eligibility criteria:
inclusion criteria: * subject signed informed consent form (icf) * age 40 and above- male with symptomatic bph. * ipss symptom severity score ≥ 13 * peak urinary flow of \< 12 ml/sec * prostate volume between 25 ml to 80 ml (assessed by pre-operative ultrasound - trus) * blood cbc and biochemistry up to two weeks before screening, demonstrating: normal values of the pt, ptt and inr tests (anticoagulants washout may be done two weeks prior of device implantation) * subject able to comply with the study protocol * normal urinalysis and negative urine culture * subjects that are able to undergo mri. exclusion criteria: * a post void residual (pvr) volume \> 250 ml measured by ultrasound or acute urinary retention * confirmed or suspected bladder cancer; * recent (within 3 months) cystolithiasis or hematuria; * urethral strictures, bladder neck contracture, urinary bladder stones or other potentially confounding bladder pathology; * an active urinary tract infection. * enrolled in another treatment trial for any disease within the past 30 days. * previous colo- rectal surgery (other than hemorrhoidectomy) or history of rectal disease if the therapy may potentially cause injury to sites of previous rectal surgery, e.g., if a transrectal probe is used; * previous pelvic irradiation, cryosurgery or radical pelvic surgery; * previous prostate surgery, balloon dilatation, stent implantation, laser prostatectomy, hyperthermia, or any other invasive treatment to the prostate * median lobe obstruction of the prostate (larger than 1cm). * cancer that is not considered cured, except basal cell or squamous cell carcinoma of the skin (cured defined as no evidence of cancer within the past 5 years) * patient with renal dysfunction * any serious medical condition likely to impede successful completion of the study
brief counseling to reduce injuries among emergency department patients who report alcohol and substance use

Conditions: Alcohol Drinking; Marijuana Smoking

Summary: the purpose of this study is to determine the effectiveness of two brief counseling sessions delivered to emergency department (ed) patients who report conjoint alcohol and marijuana use, in reducing injuries and other negative consequences, in comparison to an assessment only group.

alcohol and substance use remain a significant predictor of injuries, health and psychosocial consequences. ed patients who were not being treated for critical conditions were asked about their use of alcohol and marijuana. patients who self-reported the use of both substances were asked to participate in the study. recruited participants were given a baseline assessment and then randomized a treatment or a control condition. the treatment condition consisted of two 40 minute sessions of brief counseling. the first session took place in the ed the second session occurred within two weeks of being seen in the ed. participants completed assessments three and twelve months after being recruited in the ed. the primary dependent variables for this study are 12 month injuries and self-reported levels of negative life consequences associated with alcohol and marijuana use.

Eligibility criteria:
inclusion criteria: * male and female outpatients 18 years of age or older. * participants will have a current dsm-iv diagnosis of alcohol dependence. * participants will have signed a witnessed informed consent. exclusion criteria: * participants who meet current dsm-iv criteria for bipolar disorder, schizophrenia, dementia, or a psychological disorder requiring medication. * participants who have had more than seven days of inpatient treatment for substance use disorders in the 30 days previous to randomization.

Keywords: alcohol drinking marijuana smoking substance use emergency department (ed)
mhealth effect on multiple sclerosis patients' quality of life and self-care practices

Conditions: Multiple Sclerosis

Summary: the goal of this clinical trial is to learn if an arabic mobile application for multiple sclerosis patients will improve self-care practice and the quality of life of patients or not. the main question it aims to answer is: does the arabic mobile application for ms patients will improve their self-care and quality of life? participants will: use the developed application or usual care without using the application for 3 months be followed up during the 12 week period and asked to follow the instructions in the application

this study aims to build and test a culturally appropriate mobile application in arabic for ms (multiple sclerosis) patients in egypt. it will focus on self-care practices and quality of life enhancement via educational material provision, symptom tracking as well as medication adherence reminders among other possible functions depending on user preferences. the study shall evaluate how effective the developed app is in promoting self-care practices and improving the quality of life for ms patients compared to a control group who do not use the app.

Eligibility criteria:
inclusion criteria: * diagnosed clinically with multiple sclerosis. * from 18 to 50 years old (adult). * with smartphones. * willing to participate in the study and use the mobile application. exclusion criteria: * patients who are bedridden or in a wheelchair * illiterate patients.

Keywords: multiple sclerosis quality of life self-care mhealth arabic application
effects of ai chi on scapular muscle activation in overhead athletes with scapular dyskinesis

Conditions: Scapular Dyskinesis; Athletic Injuries; Muscle Weakness; Overuse Injury

Summary: scapular dyskinesis (sd) is common in overhead athletes and negatively influence the athletes' performance, increasing the risk of shoulder injury. the kinetic chain (kc) exercises for sd rehabilitation that emphasize importance of core strength and scapula stability during skillful performance. ai chi, the aquatic exercises performed in functional positions, which are adequate for power transfer of kc. this study will investigate the effect of kc-based water exercises, ai chi, on scapular muscles in overhead athletes with sd.

the purpose of this study is to investigate muscle activations of the upper trapezius (ut), lower trapezius (lt), serratus anterior (sa), latissimus dorsi (ld), and muscle balance ratios of ut/lt, ut/sa i in overhead athletes with sd via kc-based exercise in water and on land. kc-based exercises including the movement patterns of ai chi which consist of shoulder flexion/ extension, horizontal abduction/ adduction, internal and external rotation, scapular protraction/retraction combined with spinal rotation.

Eligibility criteria:
inclusion criteria: * the participants are overhead athletes with scapular dyskinesis (sd) who played overhead sports activities at least 3 hours/week. exclusion criteria: * the individuals who have shoulder/neck pain in recent 3 months (vas \>7/10) * severe shoulder trauma (the collision shoulder, shoulder sprains or strains) * severe scoliosis (cobb angle \> 25 degrees) * surgery of upper extremity (the shoulder, cervical spine and elbow) or cervical spine * peripheral nerve injury or neurological disease (impaired sensation or motor function: numbness, tingle, muscle weakness) * body mass index (bmi) \>25 * infectious disease (upper respiratory tract infection, skin infection, etc.)

Keywords: ai chi hydrotherapy scapular dyskinesis overhead athletes muscle balance kinetic chain
a study to compare the blood levels of sildenafil following administration of an experimental tablet vs. the conventional oral tablet in healthy subjects

Conditions: Erectile Dysfunction

Summary: this study to will compare the blood levels of sildenafil following administration of an experimental tablet vs. the conventional oral tablet.


Eligibility criteria:
inclusion criteria: * healthy males between the ages of 18 and 55 years. * body mass index of 18 to 30 kg/m2, and a total body weight \>50 kg (110 lbs). exclusion criteria: * smoking in excess of the equivalent of 5 cigarettes per day. * treatment with an experimental drug within 30 days or sildenafil, vardenafil, tadalfil within 4 days before first study dose. * develop blood pressure lowering or experience dizziness, lightheadedness when going from the laying down position to standing position.

Keywords: sildenafil, pharmacokinetics, healthy volunteer
metabolic impact of intermittent cpap

Conditions: Obstructive Sleep Apnea

Summary: obstructive sleep apnea is a risk factor for diabetes and cardiovascular disease, by unknown mechanisms. the investigators hypothesize that sleep apnea changes glucose and lipid metabolism during sleep, which over time could lead to diabetes and cardiovascular disease. this study examines metabolic changes during sleep in patients with obstructive sleep apnea. patients accustomed to continuous positive airway pressure (cpap) therapy are enrolled to undergo sleep studies, either on cpap therapy or after withdrawing from cpap for 3 nights. during sleep, blood samples are obtained so that metabolic function can be compared between sleep apnea and cpap nights.

participants with a history of moderate severe sleep apnea (ahi\>20) will be enrolled if participants meet inclusion/exclusion criteria. investigators will report to the sleep laboratory on two nights, (1) after continuing their cpap or (2) after discontinuing cpap for 3 nights. the order of observation will be randomized. a standard research dinner is provided before each study. iv's are placed so that blood can be sampled at frequent (30 min) intervals throughout the night. in the morning after each study, a glucose tolerance test and endothelial function study (endopat) are performed. serum samples will be analyzed for glucose, insulin, free fatty acids, triglycerides, hormones, and other metabolic biomarkers.

Eligibility criteria:
inclusion criteria: * history of moderate to severe obstructive sleep apnea (osa) (ahi or respiratory disturbance index (rdi)\> 10). * they must also own a cpap machine and report the ability to tolerate sleeping with or without cpap during the night. exclusion criteria: * uncontrolled hypertension with systolic blood pressure \>170 or diastolic blood pressure \> 110 * congestive heart failure * use of clonidine or nicotinic acid medication * diabetes requiring the use of insulin * known pregnancy, by urine testing in women of child-bearing age * history of falling asleep while driving, near miss * high risk occupation (pilot, commercial driver) * hemoglobin \< 10 g/dl on point of care screening

Keywords: obstructive sleep apnea cpap metabolism
acceptability of hpv-self sampling

Conditions: Cervical Cancer

Summary: this trial aimed at evaluating the acceptability of hpv self-sampling among french women eligible for cervical cancer screening (25 - 65 years old) in the region of occitanie, in the south of france. acceptability will be evaluated using an anonymous questionnaire and the main outcome of the study will be the response acceptability " yes " or " no " for hpv self-sampling. secondary outcome will be analysis of socioeconomic determinants for the acceptability of hpv self-sampling. these data will help to propose new strategies for cervical cancer screening in france, particularly to taget non-attenting populations

women will be recruted in 8 centers located in 2 departments , aude and herault (in the region of occitanie in the south of france).the questionnaire will be proposed to the women attending one of these eight centers by an investigator, who will verify the inclusion and exclusion criteria. the same person will collect the filled questionnaire. the questionnaire is anonymous and is composed of 15 questions evaluating the acceptability of hpv self-sampling and socio-economic determinants. these questionnaires will be collected and statistical analysis will be performed using appropriate tools. this study will bring informations on the acceptibility of hpv self sampling among french women eligible for cervical cancer screening in 2 departements of the south of france. self-sampling acceptability will be linked to socio-economic determinants. these data will be important to propose and evaluate new strategies to improve screening coverage, particularly of the context of the organized cervical cancer screening that will take place in france in 2018.

Eligibility criteria:
inclusion criteria: * women 25-65 years old * living in the aude or herault departments * informed patient exclusion criteria * virgins * previous hysterectomy * present or previous cervical pathology * patient under guardianship or tutorship

Keywords: women 25-65 years
bacterial and antimicrobial susceptibility profile and the prevalence of different sites of infection(baspp)

Conditions: Infectious Diseases in Pneumonia,Nephropyelitis,Angiocholitis or Others; Positive Bacterial Cultures Results of the Medical Records

Summary: positive results of bacterial culture are analyzed comprehensively in shengjing hospital of china medical university in recent 3 years（between 2015- 2017）


Eligibility criteria:
inclusion criteria: * clinical diagnosis of pneumonia, nephropyelitis, angiocholitis or other infectious diseases * positive results of bacterial cultures in blood, urine, sputum, and secretion * the medical records of shengjing hospital of china medical university from january 2015 to december 2017 exclusion criteria: * negative results of bacterial cultures in blood, urine, sputum, and secretion
cats tonometer iop reduction latanoprost verses timolol

Conditions: Glaucoma; Drugs

Summary: topical prostaglandin analog vs betablocker - corneal biomechanical evaluation using cats tonometer prism

this clinical trial is a prospective, controlled, study and will be performed at one clinical investigative site in tucson arizona1. the purpose of this study is to determine if the device, cats tonometer prism, measures intraocular pressure significantly differently than the current standard of care tonometer prism (goldmann) before and after institution of topical prostaglandin analogs (pga) for glaucoma treatment. fifty percent of patients will be randomly placed on topical beta blockers as a control. the difference pgas and beta blockers would be a measurement of the amount of corneal biomechanical changes made due to the pga controlled for the effect of iop lowering by the beta -blocker group.

Eligibility criteria:
inclusion criteria: * • male and female patients, at least 18 years of age * subject has a clear understanding and agrees to all the conditions of the informed consent form exclusion criteria: * subjects shall be selected in accordance with the following exclusion criteria * subject has undergone ocular surgery within the last 3 months * uncontrolled systemic disease that in the opinion of the investigator would put the subject's heath at risk * pregnant or nursing women * those who have had corneal surgery including corneal laser surgery * microphthalmos * buphthalmos * severe dry eyes * lid squeezers - blepharospasm * nystagmus * corneal or conjunctival infection.
brl49653c in type 2 diabetes -comparison study with pioglitazone and placebo by monotherapy-

Conditions: Diabetes Mellitus, Type 2

Summary: this study is designed to compare the efficacy and safety of brl49653c versus pioglitazone and placebo.


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus. * managed by diet therapy. * must have adequate blood, liver and kidney function. exclusion criteria: * serious cardiovascular disease or serious hepatic disease.

Keywords: rosiglitazone vandia type 2 diabetes mellitus diabetes;
effect of sitagliptin in impaired glucose tolerance

Conditions: Impaired Glucose Tolerance

Summary: the purpose of this study is to examine the safety and efficacy of sitagliptin 100 mg every day (q.d.) in improving hyperglycemia and endothelial dysfunction in subjects with impaired glucose tolerance.


Eligibility criteria:
inclusion criteria: 1. chinese subjects aged 40-65 years with fasting plasma glucose \< 100 mg/dl and ogtt 2-hour glucose 140-199 mg/dl. 2. subjects are judged to be in otherwise general good health based on medical history, physical examination, and routine laboratory tests. 3. subject has an understanding of the study procedures, alternative treatments available and risk involved with the study, and voluntarily agrees to participate by giving written informed consent. 4. non-sterilized premenopausal female agrees to receive pregnancy test to confirm the non-pregnancy status and use adequate contraceptive methods to prevent pregnancy during the study period. patient status should be confirmed by pregnancy test before enrollment. exclusion criteria: 1. evidence of diabetes (fpg\> 125 mg/dl, or ogtt 2-hour glucose\>=200 mg/dl, or current use of an anti-diabetic agents, except for history of gestational diabetes). 2. history of intolerance or hypersensitivity or contraindication as mentioned in the approved package insert (appendix). 3. patient has any of the following disorders within the past 6 months: acute coronary syndrome (e.g., mi or unstable angina), coronary artery intervention (e.g., cabg or ptca), stroke or transient ischemic neurological disorder. 4. patient has new or worsening signs or symptoms of coronary heart disease within the past 3 months. 5. patient has a bmi \> 40 kg/m2. 6. patient is on or likely to require more than 14 consecutive days or repeated courses of pharmacologic doses of corticosteroids. note: inhaled, nasal, and topical corticosteroids are permitted. 7. patient is on or likely to require treatment with immunosuppressive agents (e.g., cyclosporine, methotrexate). 8. advanced renal insufficiency (estimated creatinine clearance \< 50 ml/min). 9. severe hepatic insufficiency (child-pugh score \> 9, see appendix).
treatment of adult growth hormone deficiency after traumatic brain injury.

Conditions: Brain Injuries

Summary: to establish the effects of genotropin replacement in patients with severe growth hormone deficiency after traumatic brain injury on cognitive function.


Eligibility criteria:
inclusion criteria: * have had a previous traumatic brain injury (more than 1 year and less than 5 years) prior to the screening visit. * have an extended glasgow outcome scale (gos-e) more than or equal to 5. exclusion criteria: * active systemic malignancy or active intracranial tumor. a successfully treated tumor or malignancy is not an exclusion criterion if the patient has not had active disease for 5 years and is not currently receiving maintenance chemotherapy, (except for basal cell skin cancers. * receiving treatment with prednisolone in doses above 10 mg/day or treatment with other oral glucocorticosteroids above replacement doses is not permitted throughout the study. topical and inhaled corticosteroids are permitted.
interest of hypnosis when setting up non-invasive ventilation in a conscious patient with copd and/or obesity with a bmi greater than 30, suffering fromacute respiratory distress in adult intensive care

Conditions: Chronic Obstructive Pulmonary Disease (COPD); Obesity With a BMI Greater Than 30; Acute Respiratory Distress in Adult Intensive Care

Summary: discomfort during respiratory decompensation of a patient with chronic obstructive pulmonary disease (copd) and/or obesity with a bmi greater than 30, in intensive care and the establishment of non-invasive ventilation (niv) is frequent and a source of failure. this therapy. pharmacological treatments may be impossible due to the pathology, the risk of it worsening and adverse effects. in this context, hypnosis appears to be a tool that would promote comfort and thus increase tolerance of niv.


Eligibility criteria:
pre-inclusion criteria * man or woman, aged 18 or over, admitted to medical intensive care * glasgow score = 15 * patient with acute respiratory failure decompensating copd and/or having obesity with a body mass index (bmi) greater than 30 * patient having given free, informed and written consent * patient affiliated to a health insurance system inclusion criteria: * glasgow score = 15 * need during use of non-invasive ventilation exclusion criteria: * procedure to be carried out in extreme urgency (paco2 too high and leading to an immediate vital risk, and / or pao2 too low) on medical decision * confusional state making hypnosis impossible * decompensated psychiatric illness * patient entering with an niv in place already installed in another department. the subject becomes included again at the end of the treatment with niv if however he needs it again. * patient already included in the study during previous non-invasive ventilation * patient participating in research involving an interventional human person (category 1) on an analgesic / sedative medication * a person of full age subject to legal protection (safeguard of justice, curators, guardianship) or deprived of liberty
evaluation of the prevalence of bp180 and bp230 autoantibodies in the serum of patients with pruritus under immunotherapy

Conditions: Patients With Chronic Pruritus for More Than 1 Month Who Have Received Immunotherapy

Summary: the aim of the study is to evaluate the prevalence of positive anti bp180 and/or anti bp230 serology in the serum of patients with chronic and diffuse pruritus for at least 1 month under immunotherapy and in the absence of obvious pruritic dermatosis (e.g. scabies, contact eczema...).


Eligibility criteria:
inclusion criteria: * patient currently receiving immunotherapy (pembrolizumab, nivolumab, atezolizumab, durvalumab) as monotherapy or in combination or patient who has received immunotherapy (pembrolizumab, nivolumab, atezolizumab, durvalumab) as monotherapy or in combination within the last 6 months. * patients with chronic (\> 1 month) diffuse pruritus, which started after the start of immunotherapy and in the absence of an obvious pruritic dermatosis. * woman of childbearing age with effective contraception (see gtfg) (estrogen-progestin or intrauterine device or tubal ligation) for 1 month (negative urine/blood pregnancy test) or postmenopausal woman: confirmatory diagnosis (non-medically induced amenorrhea for at least 12 months prior to the inclusion visit) * major patient * patient having read and understood the information letter and signed the consent form * patient affiliated to a social security scheme exclusion criteria: pruritus prior to immunotherapy. bullous pemphigoid prior to immunotherapy end-stage chronic renal failure (gfr \ 34 µmol/l hepatic cholestasis diabetes mellitus complicated by diabetic neuropathy. history of polycythemia vera history of hodgkin's lymphoma iron deficiency anemia current treatment including dpp-4 inhibitors (vildagliptin, linagliptin) treatment with systemic corticosteroids or immunosuppressant for more than one month. pregnant or parturient or breastfeeding woman or absence of proven contraception · person deprived of liberty by an administrative or judicial decision or person placed under legal safeguard / sub-tutorship or curatorship